View Item 

Show simple item record

Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy

dc.contributor.authorLok, Anna S.
dc.contributor.authorPerrillo, Robert
dc.contributor.authorLalama, Christina M.
dc.contributor.authorFried, Michael W.
dc.contributor.authorBelle, Steven H.
dc.contributor.authorGhany, Marc G.
dc.contributor.authorKhalili, Mandana
dc.contributor.authorFontana, Robert J.
dc.contributor.authorSterling, Richard K.
dc.contributor.authorTerrault, Norah
dc.contributor.authorFeld, Jordan J.
dc.contributor.authorDi Bisceglie, Adrian M.
dc.contributor.authorLau, Daryl T.Y.
dc.contributor.authorHassan, Mohamed
dc.contributor.authorJanssen, Harry L.A.
dc.contributor.authorChung, Raymond T
dc.date.accessioned2021-07-01T20:13:52Z
dc.date.available2022-07-01 16:13:51en
dc.date.available2021-07-01T20:13:52Z
dc.date.issued2021-06
dc.identifier.citationLok, Anna S.; Perrillo, Robert; Lalama, Christina M.; Fried, Michael W.; Belle, Steven H.; Ghany, Marc G.; Khalili, Mandana; Fontana, Robert J.; Sterling, Richard K.; Terrault, Norah; Feld, Jordan J.; Di Bisceglie, Adrian M.; Lau, Daryl T.Y.; Hassan, Mohamed; Janssen, Harry L.A.; Chung, Raymond T (2021). "Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy." Hepatology (6): 2124-2140.
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.urihttps://hdl.handle.net/2027.42/168359
dc.publisherWiley Periodicals, Inc.
dc.publisherU.S. National Library of Medicine, NIH
dc.titleLow Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168359/1/hep31554_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168359/2/hep31554.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168359/3/hep31554-sup-0001-Supinfo.pdf
dc.identifier.doi10.1002/hep.31554
dc.identifier.sourceHepatology
dc.identifier.citedreferenceDi Bisceglie AM, Lombardero M, Teckman J, Roberts L, Janssen HL, Belle SH, et al. Determination of hepatitis B phenotype using biochemical and serological markers. J Viral Hepat 2017; 24: 320 ‐ 329.
dc.identifier.citedreferenceTong MJ, Hsien C, Hsu L, Sun HE, Blatt LM. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology 2008; 48: 1070 ‐ 1078.
dc.identifier.citedreferenceAberra H, Desalegn H, Berhe N, Mekasha B, Medhin G, Gundersen SG, et al. The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia. J Hepatol 2019; 70: 1065 ‐ 1071.
dc.identifier.citedreferenceMarcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5‐year open‐label follow‐up study. Lancet 2013; 381: 468 ‐ 475.
dc.identifier.citedreferenceWong GL, Chan HL, Mak CW, Lee SKY, Ip ZMY, Lam ATH, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58: 1537 ‐ 1547.
dc.identifier.citedreferencePapatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 2017; 66: 1444 ‐ 1453.
dc.identifier.citedreferenceWu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 2014; 147: 143 ‐ 151.e5.
dc.identifier.citedreferenceSu TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 2016; 36: 1755 ‐ 1764.
dc.identifier.citedreferencePapatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, et al. Eight‐year survival in chronic hepatitis B patients under long‐term entecavir or tenofovir therapy is similar to the general population. J Hepatol 2018; 68: 1129 ‐ 1136.
dc.identifier.citedreferenceGordon SC, Lamerato LE, Rupp LB, Li J, Holmberg SD, Moorman AC, et al. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol 2014; 12: 885 ‐ 893.
dc.identifier.citedreferenceSarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. Asian‐Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10: 1 ‐ 98.
dc.identifier.citedreferenceEuropean Association for the Study of the Liver. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370 ‐ 398.
dc.identifier.citedreferenceTerrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67: 1560 ‐ 1599.
dc.identifier.citedreferenceGhany MG, Perrillo R, Li R, Belle SH, Janssen HLA, Terrault NA, et al. Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. Clin Gastroenterol Hepatol 2015; 13: 183 ‐ 192.
dc.identifier.citedreferenceFeld JJ, Terrault NA, Lin HS, Belle SH, Chung RT, Tsai N, et al. Entecavir and peginterferon alfa‐2a in adults with hepatitis B e antigen‐positive immune‐tolerant chronic hepatitis B virus infection. Hepatology 2019; 69: 2338 ‐ 2348.
dc.identifier.citedreferenceUniversity of Pittsburgh, National Center for Research Resources. Combination Therapy of Pegylated Interferon Alfa‐2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B (HBRN). ClinicalTrials.gov Identifier: NCT01369212. Bethesda, MD: U.S. National Library of Medicine, NIH; 2020.
dc.identifier.citedreferenceGanova‐Raeva L, Ramachandran S, Honisch C, Forbi JC, Zhai X, Khudyakov Y. Robust hepatitis B virus genotyping by mass spectrometry. J Clin Microbiol 2010; 48: 4161 ‐ 4168.
dc.identifier.citedreferenceIloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678 ‐ 686.
dc.identifier.citedreferenceWai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518 ‐ 526.
dc.identifier.citedreferenceSterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317 ‐ 1325.
dc.identifier.citedreferenceYu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145: 1039 ‐ 1047.
dc.identifier.citedreferenceChen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65 ‐ 73.
dc.identifier.citedreferenceIloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007; 5: 921 ‐ 931.
dc.identifier.citedreferenceYang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134 ‐ 1143.
dc.identifier.citedreferenceYang JD, Altekruse SF, Nguyen MH, Gores GJ, Roberts LR. Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. Cancer 2017; 123: 81 ‐ 89.
dc.identifier.citedreferenceHoang JK, Yang HI, Le A, Nguyen NH, Lin D, Vu VD, et al. Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis. Medicine (Baltimore) 2016; 95: e4433.
dc.identifier.citedreferenceShim JJ, Kim JW, Oh CH, Lee YR, Lee JS, Park SY, et al. Serum alanine aminotransferase level and liver‐related mortality in patients with chronic hepatitis B: a large national cohort study. Liver Int 2018; 38: 1751 ‐ 1759.
dc.identifier.citedreferenceChoi GH, Kim GA, Choi J, Han S, Lim YS. High risk of clinical events in untreated HBeAg‐negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther 2019; 50: 215 ‐ 226.
dc.identifier.citedreferenceHsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long‐term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522 ‐ 1527.
dc.identifier.citedreferenceKim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 2014; 63: 1325 ‐ 1332.
dc.identifier.citedreferenceLiu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrla‐Utermann R, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut 2014; 63: 1648 ‐ 1657.
dc.identifier.citedreferenceLe MH, Yeo YH, Cheung R, Henry L, Lok AS, Nguyen MH. Chronic hepatitis B prevalence among foreign‐born and U.S.‐born adults in the United States, 1999‐2016. Hepatology 2020; 71: 431 ‐ 443.
dc.identifier.citedreferenceLiaw YF. Natural history of chronic hepatitis B virus infection and long‐term outcome under treatment. Liver Int 2009; 29 ( Suppl. 1 ): 100 ‐ 107.
dc.identifier.citedreferenceIloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int 2012; 32: 1333 ‐ 1341.
dc.identifier.citedreferenceFattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335 ‐ 352.
dc.identifier.citedreferencePapatheodoridis GV, Manesis E, Hadziyannis SJ. The long‐term outcome of interferon‐alpha treated and untreated patients with HBeAg‐negative chronic hepatitis B. J Hepatol 2001; 34: 306 ‐ 313.
dc.identifier.citedreferenceYu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97: 265 ‐ 272.
dc.identifier.citedreferenceShimakawa Y, Lemoine M, Njai HF, Bottomley C, Ndow G, Goldin RD, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population‐based study from The Gambia. Gut 2016; 65: 2007 ‐ 2016.
dc.identifier.citedreferenceChing LK, Gounder PP, Bulkow L, Spradling PR, Bruce MG, Negus S, et al. Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska Native people. Liver Int 2016; 36: 1507 ‐ 1515.
dc.identifier.citedreferenceMcMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49 ( 5 Suppl. ): S45 ‐ S55.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hep31554_am.pdf
Size:
448.7KB
Format:
PDF
View/Open
Name:
hep31554.pdf
Size:
263.0KB
Format:
PDF
View/Open
Name:
hep31554-sup-0001-Supinfo.pdf
Size:
519.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.